newsroom >   press release highlights

Press Release Highlights

03.31.2015
Syndax and Merck to Collaborate on Immuno-Oncology Study Evaluating Entinostat in Combination with KEYTRUDA® (pembrolizumab) in Lung Cancer and Melanoma

03.12.2015
Syndax to Participate in Two Upcoming Conferences

02.05.2015
Syndax to Present at 2015 BIO CEO & Investor Conference

01.07.2015
Kyowa Hakko Kirin and Syndax Announce an Exclusive License Agreement to Develop and Commercialize Entinostat in Japan and Korea

07.30.2014
Entinostat Improves Treatment Outcomes When Combined with Immune Checkpoint Blockade in Preclinical Tumor Models

06.30.2014
First Patient Enrolled in ECOG-ACRIN Phase III Trial of Syndax’s Entinostat

05.27.2014
Syndax Announces Presentation of Entinostat Data in Two Posters at the 2014 American Society of Clinical Oncology(ASCO) Annual Meeting

03.27.2014
Syndax Files Registration Statement for Proposed Initial Public Offering

03.21.2014
ECOG-ACRIN Cancer Research Group Opens Phase III Trial of Syndax’s Entinostat in Advanced Breast Cancer

02.13.2014
Syndax Announces NCI and FDA Reach Agreement on a Special Protocol Assessment (SPA) for the Phase 3 Trial of Entinostat in Patients with Advanced ER+ Breast Cancer

02.03.2014
Leading Breast Cancer Expert, George W. Sledge, Jr., M.D., Joins Syndax as an Independent Director

01.23.2014
Syndax Announces Appointment of Richard P. Shea as Independent Director and Chair of the Audit Committee

2013 Archived Press Releases

2012 Archived Press Releases

2011 Archived Press Releases

2010 Archived Press Releases

Older Archived Press Releases

For media inquiries please email info@syndax.com.